Does Cabergoline Help in Decreasing Chronic Pelvic Pain Due to Endometriosis Compared to Medroxyprogesterone Acetate? A Prospective Randomized Study

Amit Kyal, Atri Pal, Aprateem Mukhopadhyay, Partha Mukhopadhyay

ABSTRACT

Introduction: Endometriosis is a chronic debilitating disease which adversely affects the equality of life of the woman. The exact pathophysiology of the disease and cause of pain is not clearly understood and so confounds an attempt to select the most favourable clinical management. The study aims to assess the safety and efficacy of cabergoline with respect to medroxyprogesterone acetate in treatment of chronic pelvic pain (CPP) due to endometriosis.

Materials and methods: This study was conducted in Medical College, Kolkata from June 2015 to June 2016. Eighty patients of chronic pelvic pain due to endometriosis (diagnosed by USG and laparoscopy) were randomly assigned into two groups of 40 each receiving either medroxyprogesterone acetate (10 mg TDS) or cabergoline (0.5 mg twice weekly) for 12 weeks. Response for pain was measured on a visual analog scale (VAS) of 0–10 scale at the beginning of treatment and at intervals of 1, 3, 4 and 6 months.

Results: The study shows that the decrease in pain scores at various time points was statistically significant in both the groups. However, when the two groups were compared among themselves the reduction in VAS score at various time points were not statistically significant. Patients receiving medroxyprogesterone acetate had more side effects (67.5%) compared to cabergoline (47.5%). The most common side effect in medroxyprogesterone acetate group was amenorrhea (25%) whereas, in the cabergoline group, it was nausea and vomiting (45%).

Conclusion: Cabergoline and medroxyprogesterone acetate are equally effective in decreasing chronic pelvic pain due to endometriosis. However, due to lesser side effects and less frequent dosing, cabergoline has a better acceptance and compliance than medroxyprogesterone acetate. Thus cabergoline can be a better alternative to medroxyprogesterone acetate.

Keywords: Cabergoline, Chronic pelvic pain, Endometriosis, Medroxyprogesterone acetate.

INTRODUCTION

Endometriosis is a chronic debilitating disease which adversely affects the quality of life of the woman. Prevalence at present is around 10%.1 Endometriosis is a very common cause of CPP2 and is found in as much as 20 to 90% of the patients.

The exact pathophysiology of the disease and the cause of pain is not clearly understood and thus confounds an attempt to select the most favorable clinical management.

Neovascularization has a pivotal role in the development of endometriosis.3 Amongst the known angiogenic factors, Vascular endothelial growth factor (VEGF) has been found to as the most important regulator of normal angiogenesis and neovascularization. Increased VEGF is found in the endometriotic lesion and peritoneal fluid of patients with endometriosis.4,5 So cabergoline can be a novel drug for the treatment of chronic pelvic pain due to endometriosis.

It has been found from recent studies that neurotransmitter dopamine inhibits VEGF induced angiogenesis at nontoxic doses.6 Dopamine and its agonists, such as cabergoline, promote VEGF receptor-2 endocytosis in endothelial cells, therefore VEGF-VEGFR-2 binding is prevented and neoangiogenesis is decreased.7 It has been found that daily treatment with cabergoline suppresses cell proliferation and VEGF mediated angiogenesis thereby helping in regression of endometriotic lesions.8 So cabergoline can be a novel drug for the treatment of chronic pelvic pain due to endometriosis.

Medroxyprogesterone acetate is a commonly used, cheap, easily available drug for treatment of endome-
triosis. The present research proposal is to systematically study the effect of cabergoline on chronic pelvic pain due to endometriosis in comparison with medroxyprogesterone acetate.

MATERIALS AND METHODS

The study was conducted in Department of Gynaecology and Obstetrics, Medical College, Kolkata from July 2015 to June 2016. It was a prospective comparative interventional study. Eighty patients in the age group 25 to 40 years and suffering from chronic pelvic pain who were diagnosed with the help of USG and laparoscopy to suffer from endometriosis, were included in the study after institutional ethics approval and consent from the study subjects. Patients with abnormal LFT, renal impairment, heart disease, uncontrolled hypertension and diabetes mellitus were excluded. The patients were randomized and assigned into two groups (groups M and C) of 40 each. Group M received medroxyprogesterone acetate (10 mg TDS daily), and group C received cabergoline (0.5 mg twice weekly) for 12 weeks. The response of the patient for pain was measured on a VAS of 0 to 10 at the beginning of treatment and after that at 1, 3, 4 and 6 months. Data collected were tabulated and analyzed as per standard statistical protocol. The p-value ≤ 0.05 were considered significant.

RESULTS

Eighty patients with chronic pelvic pain due to endometriosis were randomly divided into two groups of 40 each. Group M received medroxyprogesterone acetate, and group C received cabergoline for 12 weeks respectively, and the VAS score was recorded at various time points.

Mean age of patients in group M, and C were 29.55 and 29.65 respectively (Table 1). Applying the unpaired t-test no statistically significant difference was found between the two groups (p > 0.05).

Table 1: Comparison of age (in years) between the two groups

<table>
<thead>
<tr>
<th>Group Name</th>
<th>Mean</th>
<th>Median</th>
<th>S.D</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>29.55</td>
<td>28.0</td>
<td>3.038</td>
<td>26</td>
<td>37</td>
<td>11</td>
</tr>
<tr>
<td>C</td>
<td>29.65</td>
<td>29.0</td>
<td>3.000</td>
<td>26</td>
<td>38</td>
<td>12</td>
</tr>
</tbody>
</table>

In our study, the mean VAS for Group M at the beginning was 8.93 and at 1 month, 3 months, 4 months and 6 months were 5.78, 4.30, 3.75, and 4.13 respectively. By applying ANOVA the decrease in the pain score was found to be statistically significant when compared to the VAS at the beginning (p < 0.05 ). However, there was an increase in VAS score at 6 months when compared to that of 4 months (Table 2).

Mean VAS for group C at the beginning was 8.93 and at 1, 3, 4, 6 months were 5.78, 4.30, 3.75, 4.13 respectively. By applying analysis of variance (ANOVA) the decrease in the VAS score was found to be statistically significant when compared to the VAS at the beginning (p < 0.05 ). Similarly, in group C there was an increase in pain score at 6 months when compared to that of 4 months as seen in group M (Table 3).

Comparing the VAS score of the two groups (groups M and C) across various time points, there was no statistically significant difference between them (Table 4). Group C (47.5%) had lesser side effects compared to group M (67.5%). The most common side effect in medroxyprogesterone acetate group was amenorrhea (25%) whereas, in the cabergoline group, it was nausea and vomiting (45%) (Table 5).

Table 4: Comparison of effect of medroxyprogesterone acetate (M) and cabergoline (C) on VAS scores at various time points

<table>
<thead>
<tr>
<th>VAS at beginning</th>
<th>M</th>
<th>C</th>
<th>S.D</th>
<th>Range</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean 8.93*</td>
<td>9.00</td>
<td>8.93*</td>
<td>0.730</td>
<td>2</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>9.00</td>
<td>9.00</td>
<td>6.00</td>
<td>2</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>SD</td>
<td>0.730</td>
<td>0.730</td>
<td>1.023</td>
<td>4</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Minimum</td>
<td>8</td>
<td>8</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Maximum</td>
<td>10</td>
<td>10</td>
<td>6</td>
<td>6</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

In our study, the mean VAS in the group receiving medroxyprogesterone acetate across various time points was 8.93 and at 1 month, 3 months, 4 months and 6 months were 5.78, 4.30, 3.75, and 4.13 respectively. By applying ANOVA the decrease in the pain score was found to be statistically significant when compared to the VAS at the beginning (p < 0.05 ). However, there was an increase in VAS score at 6 months when compared to that of 4 months (Table 2).

Mean VAS for group C at the beginning was 8.93 and at 1, 3, 4, 6 months were 5.78, 4.30, 3.75, 4.13 respectively. By applying analysis of variance (ANOVA) the decrease in the VAS score was found to be statistically significant when compared to the VAS at the beginning (p < 0.05 ). Similarly, in group C there was an increase in pain score at 6 months when compared to that of 4 months as seen in group M (Table 3).

Comparing the VAS score of the two groups (groups M and C) across various time points, there was no statistically significant difference between them (Table 4). Group C (47.5%) had lesser side effects compared to group M (67.5%). The most common side effect in medroxyprogesterone acetate group was amenorrhea (25%) whereas, in the cabergoline group, it was nausea and vomiting (45%) (Table 5).
CONCLUSION

At present there are a number of medical and surgical treatment available for endometriosis, however none of these are effective on long term basis and each treatment modality has its own advantages and disadvantages. Vasculogenesis is an integral part of pathogenesis of endometriosis. Cabergoline inhibits neovasculogenesis and can be a new and better alternative to conventional therapy. Endometriosis is a chronic disease. Long term investigations are required to elucidate superiority of long term administration of cabergoline compared to currently available endocrine therapies in terms of decrease of pain, side effect profile and patient satisfaction. Let us give women a pain free today for a better tomorrow.

REFERENCES